Entellus Medical Inc. (NASDAQ:ENTL) shares saw an uptick in trading volume on Monday . 54,617 shares traded hands during trading, a decline of 24% from the previous session’s volume of 71,469 shares.The stock last traded at $18.27 and had previously closed at $18.20.

Several equities analysts have weighed in on ENTL shares. Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a research report on Thursday, April 14th. BTIG Research began coverage on Entellus Medical in a research report on Tuesday, June 14th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Canaccord Genuity reissued a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a research report on Wednesday, June 29th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Entellus Medical presently has an average rating of “Buy” and a consensus target price of $23.80.

The company has a 50-day moving average price of $18.17 and a 200 day moving average price of $16.84. The company’s market capitalization is $343.62 million.

Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Wednesday, May 4th. The medical technology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.10. The business had revenue of $16.90 million for the quarter, compared to the consensus estimate of $16.34 million. The company’s revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.35) earnings per share. On average, analysts predict that Entellus Medical Inc. will post ($1.32) EPS for the current year.

An institutional investor recently raised its position in Entellus Medical stock. Wells Fargo & Company MN increased its position in shares of Entellus Medical Inc. (NASDAQ:ENTL) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 464,550 shares of the medical technology company’s stock after buying an additional 31,082 shares during the period. Wells Fargo & Company MN owned about 2.47% of Entellus Medical worth $7,832,000 at the end of the most recent reporting period.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.